Bicara Therapeutics Inc.

BCAX

Explore Our Financial Data > Companies > Massachusetts Companies > Bicara Therapeutics Inc.
{{popupValue}}
{{popupSubtitle}}
Documentation
Excel
API
Download

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker
BCAX
CIK0002023658
SIC2834
SectorManufacturing
Industry CategoryPharmaceutical Products
Industry GroupPharmaceutical Preparations

Contact

Address245 MAIN STREET, CAMBRIDGE, MA, 02142
Website www.bicara.com
Phone617-785-8308
CEOClaire Mazumdar
EmployeesN/A

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement
RevenueN/A
Pre-Tax Income$-157.12 million
Net Income$-157.32 million
Net Income to Common$-157.32 million
EPS$-2.77
View All
Balance Sheet
Cash$323.46 million
Assets$553.60 million
Liabilities$39.64 million
Common Equity$513.96 million
Liabilities & Equity$553.60 million
View All
Cash Flow Statement
Net Income$-157.32 million
Cash From Operating Activities$-116.24 million
Cash From Investing Activities$-217.51 million
Cash From Financing Activities$195.15 million
Change in Cash$-138.60 million
View All
Calculations
NOPAT$-121.84 million
EBITDA$-173.29 million
Price to EarningsN/A
Price to Book$2.41
ROE-32.34%
View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

A Look At Bicara Therapeutics (BCAX) Valuation After Recent Share Price Pullback

Recent trading performance and context Bicara Therapeutics (BCAX) has drawn investor attention after a choppy stretch in the stock, with shares down about 5% over the past day and roughly 16% over the past week. See our latest analysis for Bicara Therapeutics. Set against a 37% 3 month share price return and a 26.82% 1 year total shareholder return, the recent pullback suggests momentum has cooled as investors reassess Bicara Therapeutics at its latest US$19.29 share price. If you are...

Article Link

Bicara Stock Is Up 50%, and One Biotech Investor Has Made It a 29% Portfolio Bet

This clinical-stage biotech develops bifunctional antibody therapies targeting solid tumors for oncology providers and institutions.

Article Link

Alumis Stock Is Up Over 300%. One Major Healthcare Investor Is Cutting Back

Alumis Inc. develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases using allosteric TYK2 inhibitors.

Article Link

Bicara Therapeutics Touts Cancer Drug Progress Ahead of 2026 Pivotal Data

Bicara Therapeutics (NASDAQ:BCAX) said its lead cancer drug candidate, ficerafusp alfa, remains on track for pivotal data in head and neck cancer in mid-2026, as the company outlined its development strategy and competitive positioning at the Bank of America Healthcare Conference. Ryan Kohlhepp of

Article Link

Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

BOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that, effective May 8, 2026, it awarded an inducement grant to Christopher Sarchi under Bicara’s 2026 Inducement Plan as a material inducement to his commencement of employment as Bicara’s Chief Commercial Officer. Mr. Sarchi received a non-qualified stock option to p

Article Link